MOBERG PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.148 EUR | -0.06% |
|
+3.35% | +129.78% |
| 06-25 | Moberg Pharma Raises SEK336 Million from Share Sale | MT |
| 05-14 | Moberg Pharma AB Elects Jonas Ekblom as Board Member | CI |
| Sales 2024 * | 6M 567K 520K 775K | Sales 2025 * | 42M 3.97M 3.64M 5.43M | Capitalization | 1.71B 162M 148M 221M |
|---|---|---|---|---|---|
| Net income 2024 * | -29M -2.74M -2.51M -3.75M | Net income 2025 * | -22M -2.08M -1.91M -2.84M | EV / Sales 2024 * | 246 x |
| Net cash position 2024 * | 239M 22.53M 20.68M 30.82M | Net cash position 2025 * | 199M 18.79M 17.24M 25.7M | EV / Sales 2025 * | 36 x |
| P/E ratio 2024 * |
-5.24
x | P/E ratio 2025 * |
-7.34
x | Employees | 9 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.86% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.06% | ||
| 1 week | +3.35% | ||
| Current month | +26.43% | ||
| 1 month | +42.31% | ||
| 3 months | +18.88% | ||
| 6 months | +128.12% | ||
| Current year | +129.78% |
1 week
2.97
3.34
1 month
2.293.34
Current year
1.143.36
1 year
0.493.36
3 years
0.497.33
5 years
0.4974.70
10 years
0.4974.70
| Managers | Title | Age | Since |
|---|---|---|---|
Anna Ljung
CEO | Chief Executive Officer | 44 | 05-12-31 |
Mark Beveridge
DFI | Director of Finance/CFO | 46 | 14-12-31 |
| Chief Tech/Sci/R&D Officer | 60 | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anders Lundmark
BRD | Director/Board Member | 66 | 22-05-15 |
Håkan Wallin
BRD | Director/Board Member | 62 | 23-05-15 |
Nikolaj Sørensen
BRD | Director/Board Member | 52 | 20-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 3.148 | -0.06% |
| 24-07-15 | 3.15 | -3.43% |
| 24-07-12 | 3.262 | +3.95% |
| 24-07-11 | 3.138 | +2.82% |
| 24-07-10 | 3.052 | +0.20% |
Delayed Quote Deutsche Boerse AG, July 16, 2024 at 05:05 am
More quotes
Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +61.53% | 856B | |
| +38.95% | 631B | |
| -3.66% | 359B | |
| +15.06% | 325B | |
| +9.18% | 297B | |
| +5.89% | 234B | |
| +16.53% | 226B | |
| +15.67% | 177B | |
| +2.47% | 165B |
- Stock Market
- Equities
- MOB Stock
- MB8 Stock
